drugset
drugset / Trial / NCT04857307

A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy

NCT04857307 ↗

Phase 1 Completed 14 enrolled UCB Biopharma SRL
NaSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to assess the pharmacokinetics (PK), tolerability, and safety of Staccato alprazolam in adolescent study participants with epilepsy following single-dose administration.

Timeline

Start
2021-04-28
Primary completion
2022-04-05
Completion
2022-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule — Inhaled

Indications

epilepsy